Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan; Department of Cardiology, Osaka Medical and Pharmaceutical University, Takatsuki, Japan.
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan; Cardiovascular Respiratory Sleep Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.
Nutr Metab Cardiovasc Dis. 2022 Feb;32(2):365-372. doi: 10.1016/j.numecd.2021.10.012. Epub 2021 Oct 23.
Frailty and sarcopenia are common and confer poor prognosis in elderly patients with heart failure; however, gender differences in its prevalence or prognostic impact remain unclear.
We included 1332 patients aged ≥65 years, who were hospitalized for heart failure. Frailty and sarcopenia were defined using the Fried phenotype model and Asian Working Group for Sarcopenia criteria, respectively. Gender differences in frailty and sarcopenia, and interactions between sex and prognostic impact of frailty/sarcopenia on 1-year mortality were evaluated. Overall, 53.9% men and 61.0% women and 23.7% men and 14.0% women had frailty and sarcopenia, respectively. Although sarcopenia was more prevalent in men, no gender differences existed in frailty after adjusting for age. On Kaplan-Meier analysis, frailty and sarcopenia were significantly associated with 1-year mortality in both sexes. On Cox proportional hazard analysis, frailty was associated with 1-year mortality only in men, after adjusting for confounding factors (hazard ratio [HR], 1.94; 95% confidence interval [CI], 1.19-3.16; P = 0.008 for men; HR, 1.63; 95% CI, 0.84-3.13; P = 0.147 for women); sarcopenia was an independent prognostic factor in both sexes (HR, 1.93; 95% CI, 1.13-3.31; P = 0.017 for men; HR, 3.18; 95% CI, 1.59-5.64; P = 0.001 for women). There were no interactions between sex and prognostic impact of frailty/sarcopenia (P = 0.806 for frailty; P = 0.254 for sarcopenia).
Frailty and sarcopenia negatively affect older patients with heart failure from both sexes.
This study was registered at the University Hospital Information Network (UMIN-CTR, unique identifier: UMIN000023929) before the first patient was enrolled.
衰弱和肌少症在老年心力衰竭患者中较为常见,且预后不良;然而,其患病率或预后影响的性别差异尚不清楚。
我们纳入了 1332 名年龄≥65 岁、因心力衰竭住院的患者。使用 Fried 表型模型和亚洲肌少症工作组标准分别定义衰弱和肌少症。评估了性别在衰弱和肌少症方面的差异,以及性别与衰弱/肌少症对 1 年死亡率的预后影响之间的交互作用。总体而言,53.9%的男性和 61.0%的女性以及 23.7%的男性和 14.0%的女性存在衰弱和肌少症。尽管男性中肌少症更为常见,但在调整年龄后,两性之间的衰弱并无差异。在 Kaplan-Meier 分析中,衰弱和肌少症在两性中均与 1 年死亡率显著相关。在 Cox 比例风险分析中,在调整混杂因素后,衰弱仅与男性的 1 年死亡率相关(风险比 [HR],1.94;95%置信区间 [CI],1.19-3.16;P=0.008 男性;HR,1.63;95% CI,0.84-3.13;P=0.147 女性);肌少症是两性的独立预后因素(HR,1.93;95% CI,1.13-3.31;P=0.017 男性;HR,3.18;95% CI,1.59-5.64;P=0.001 女性)。性别与衰弱/肌少症的预后影响之间无交互作用(P=0.806 男性;P=0.254 女性)。
衰弱和肌少症对来自两性的老年心力衰竭患者产生负面影响。
本研究在首例患者入组前已在大学医院信息网(UMIN-CTR,唯一标识符:UMIN000023929)注册。